Deep Track Capital
Deep Track Capital is a Greenwich, Connecticut-based investment firm founded in 2020 that invests exclusively in life sciences, providing equity capital, strategic expertise, and network access to public and pre-IPO biotechnology companies through private financings, PIPEs, and public-market offerings.
- Company typePrivate
- Founded2020
- HeadquartersGreenwich, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Deep Track Capital does
Deep Track Capital is a Greenwich, Connecticut-based investment firm founded in 2020 by David Kroin that invests exclusively in the life sciences sector. The firm develops long-term partnerships with management teams of leading innovative public and pre-IPO biotechnology companies, providing equity capital, time, strategic expertise, and access to an extensive industry network. The strategy spans both private financings (Series A through D) and public-market transactions (PIPEs, underwritten offerings, private placements), with the firm regularly leading rounds or building large investor syndicates alongside tier-one specialists such as RA Capital, Janus Henderson, Frazier Life Sciences, Orbimed, Bain Capital Life Sciences, and Perceptive Advisors. Its portfolio is therapeutically diversified across oncology, autoimmune disease, CNS/neurology, metabolic disease (including GLP-1 and MASH), cell and gene therapy, and rare disease.
The firm operates with approximately 11–50 employees structured around an investment team (Founder/CIO David Kroin plus Managing Directors Brett Erkman, Rebecca Luse, Rael Mazansky MD/MBA, and Gerard Smith MD/MBA, plus an analyst pipeline drawn from Guggenheim, Evercore, Bain Capital Life Sciences, Leerink/SVB Leerink, Canaan Partners, and McKinsey) and an operating team led by COO/CFO Nir Messafi, Head of Business Development Jeremy Joseph, and Senior Controller Brian Diminich. Team credentials skew heavily toward specialized biomedical training, with multiple MDs and PhDs supplementing buy-side and sell-side biotech investing experience at firms including Great Point Partners, Perceptive Life Sciences, Citadel/Surveyor Capital, Leerink, and Bain Capital Life Sciences.
Revenue is generated through investment management activities (management fees and performance fees on committed capital across public and private vehicles); AUM and fee structures are not publicly disclosed. Go-to-market is relationship-driven, with dedicated inbound channels for private-company funding ([email protected]) and public-company funding ([email protected]), supplemented by conference participation and direct outreach to biotech management teams. The firm is privately held and employee-owned with no disclosed parent company or institutional ownership.
Deep Track Capital firmographics
Firmographics- Name
- Deep Track Capital
- Legal name
- Deep Track Capital
- Website
- https://deeptrackcapital.com
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Deep Track Capital is a Greenwich, Connecticut-based investment firm founded in 2020 that invests exclusively in life sciences, providing equity capital, strategic expertise, and network access to public and pre-IPO biotechnology companies through private financings, PIPEs, and public-market offerings.
- Ownership category
- akta.pro rank
Deep Track Capital industry classification
Industry- Product category
- Biotechnology Investment Management
- NAICS
- Portfolio Management and Investment Advice (523940), Other Financial Investment Activities (5239)
- SIC
- Investment Advice (6282)
- akta.pro primary industry
- Sector-Focused Venture Capital (Vertical Specialists) (FSANAAAD)
- akta.pro secondary industries
- Sector-Focused Equity Long/Short (FSAHAAAC), Late-Stage Venture Capital (Series C+) (FSANAAAC)
Keywords
Where Deep Track Capital is headquartered
LocationHeadquarters
- HQ city
- Greenwich
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Deep Track Capital business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Infrastructure, Marketing or Sales, Others
Revenue model
- Investment Management: Deep Track Capital generates returns through equity investments in biotechnology companies. The firm earns returns through capital appreciation and exits from its portfolio companies. Revenue is derived from management of investment capital in public and private biotech companies.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels2 records
Deep Track Capital product offering
Product offeringCore offering
Deep Track Capital is a Greenwich, Connecticut-based investment firm focused exclusively on the life sciences industry. The firm develops long-term partnerships with management teams of leading innovative public and pre-IPO biotechnology companies, providing equity capital, strategic expertise, and network access. The firm seeks to lead transactions while building large investor syndicates, and also invests in rounds led by other qualified investors across private placements, public offerings, and PIPE financings.
Product overview
Deep Track Capital is a single-service investment offering focused exclusively on the life sciences and biotechnology sector. The firm provides equity capital to public and pre-IPO biotechnology companies, seeking to develop long-term partnerships with management teams while investing its time, expertise, and network for the benefit of its portfolio companies. The firm aims to lead transactions while building large syndicates, and also invests in rounds led by other qualified investors.
Differentiator
Problem solved
Functional benefit
Products and services
- Biotechnology Investment Services
Companies that use Deep Track Capital
Customer profileSegments1 record
Ideal customer profiles1 record
Deep Track Capital technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Deep Track Capital partnerships and signals
Strategic signalScale indicators1 record
Recent moves6 records
Expansion highlights5 records
Deep Track Capital competitors and assessment
Company assessmentDirect peers
- RA Capital Management: Healthcare-focused crossover fund investing across private and public biotech stages. Deep Track Capital co-invests with RA Capital on multiple documented financings (Altimmune, Triveni Bio, Terremoto Biosciences, Hemab Therapeutics).
- Baker Bros. Advisors: One of the largest biotech-focused crossover funds, investing across public equities and private financings. Closely comparable to Deep Track's specialist biotech crossover model at meaningfully larger AUM scale.
- Perceptive Advisors: Healthcare-focused investment firm with crossover exposure across private and public biotech. Deep Track co-invested with Perceptive Advisors on Solid Biosciences and Mentari Therapeutics financings.
- OrbiMed: Dedicated healthcare investment firm across private equity, venture, public equity, and credit strategies. Terremoto Biosciences' round included OrbiMed as an existing investor alongside Deep Track.
- Frazier Life Sciences: Pure-play biotech venture firm investing across private and public stages. Deep Track co-invested on cAMPfield Therapeutics, Maze Therapeutics Series D, and other rounds.
- EcoR1 Capital: Biotech-focused crossover fund investing in private rounds and public equities. Similar fund construction (small, specialist, biotech-only) to Deep Track Capital.
- Cormorant Asset Management: Healthcare-focused investment manager with crossover exposure to biotech public and private financings. Closely comparable specialist biotech investor.
- Great Point Partners: Founder David Kroin's prior firm; healthcare-focused long/short and private equity. Multiple Deep Track team members (Kroin, Erkman, Szeto, Hakim) came directly from Great Point, making it the closest institutional comparable.
- Consonance Capital: Healthcare-focused investment manager. Senior Controller Brian Diminich previously served as Controller at Consonance, indicating direct operational and strategy comparability to Deep Track Capital.
Broad incumbents
- Janus Henderson Investors: Large diversified asset manager with a significant biotech crossover capability. Repeated co-investor with Deep Track (Triveni Bio, Maze, ProMIS, Diagonal Therapeutics).
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Deep Track Capital financial estimates
Financial estimateRevenue estimate
Valuation estimate
Deep Track Capital leadership team
Management profileNumber of profiles
Profiles8 records
Deep Track Capital funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Deep Track Capital M&A and investment
M&A and investmentM&A
Investments122 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Deep Track Capital
What does Deep Track Capital do?
Deep Track Capital is a Greenwich, Connecticut-based investment firm focused exclusively on the life sciences industry. The firm develops long-term partnerships with management teams of leading innovative public and pre-IPO biotechnology companies, providing equity capital, strategic expertise, and network access. The firm seeks to lead transactions while building large investor syndicates, and also invests in rounds led by other qualified investors across private placements, public offerings, and PIPE financings.
Is Deep Track Capital a public or private company?
Deep Track Capital is a private company. It is classified as management employee owned and is currently operating.
When was Deep Track Capital founded?
Deep Track Capital was founded in 2020. It employs 11 to 50 people.
Where is Deep Track Capital based?
Deep Track Capital is headquartered in Greenwich, United States, in the North America region.
How does Deep Track Capital make money?
One revenue line is on record: investment Management.
Who are Deep Track Capital's main competitors?
Direct peers on record are RA Capital Management, Baker Bros. Advisors, Perceptive Advisors, OrbiMed, Frazier Life Sciences, EcoR1 Capital, Cormorant Asset Management, Great Point Partners and Consonance Capital. Janus Henderson Investors is listed as a broad incumbent.
Does Deep Track Capital have an API?
No public API is recorded for Deep Track Capital.
What industry is Deep Track Capital in?
Deep Track Capital's product category is Biotechnology Investment Management. Its primary akta.pro industry code is FSANAAAD, Sector-Focused Venture Capital (Vertical Specialists), with a secondary code of FSAHAAAC, Sector-Focused Equity Long/Short. Its NAICS code is 523940 and its SIC code is 6282.